STOK vs. ARWR, IBRX, OGN, APLS, XENE, NAMS, GMTX, BHC, AGIO, and TWST
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Stoke Therapeutics vs. Its Competitors
Stoke Therapeutics (NASDAQ:STOK) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Stoke Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Stoke Therapeutics currently has a consensus price target of $25.80, suggesting a potential upside of 90.97%. Arrowhead Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 168.85%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Stoke Therapeutics.
Stoke Therapeutics has a net margin of 26.33% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Stoke Therapeutics' return on equity of 19.08% beat Arrowhead Pharmaceuticals' return on equity.
In the previous week, Stoke Therapeutics and Stoke Therapeutics both had 10 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 0.82 beat Stoke Therapeutics' score of 0.60 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.
Stoke Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Summary
Stoke Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:STOK) was last updated on 7/24/2025 by MarketBeat.com Staff
Free STOK Stock Alerts